Molecular Characteristics
Complete Specifications
Structural Composition
Modified 29-amino-acid GRF (1–29) sequence with targeted substitutions and a lysine-linked Drug Affinity Complex (maleimidopropionic acid modification)
Physical Properties
CJC-1295 (with DAC) is a modified 29-amino-acid peptide derived from growth hormone–releasing factor (GRF 1–29) and conjugated to a Drug Affinity Complex (DAC). The DAC moiety enables covalent binding to circulating proteins under research conditions, enhancing structural persistence compared to non-DAC variants. Targeted amino acid substitutions improve resistance to enzymatic degradation, while lyophilized presentation supports long-term storage stability. Protection from moisture, light, and repeated freeze–thaw cycles helps maintain peptide integrity for laboratory and analytical applications.
Research Applications
Growth Hormone Releasing Hormone (GHRH) Research
CJC-1295 (with DAC) is utilized as a research compound in studies examining prolonged growth hormone–releasing hormone (GHRH) receptor signaling and sustained endocrine modulation. Laboratory investigations focus on its role in:
- GHRH Receptor Activation Models: Investigation of receptor binding dynamics and extended downstream signaling cascades
- Sustained Growth Hormone Signaling: Evaluation of prolonged hormone release patterns under experimental conditions
- cAMP and Secondary Messenger Pathways: Analysis of intracellular signaling mechanisms triggered by long-acting receptor engagement
- Endocrine Feedback Regulation: Examination of pituitary and hypothalamic feedback loops during sustained stimulation
- Drug Affinity Complex (DAC) Binding Studies: Investigation of albumin binding and extended circulation time characteristics
Experimental protocols commonly employ receptor-binding assays, pituitary cell culture systems, and longitudinal hormone secretion models to characterize CJC-1295 (with DAC)–mediated signaling responses.
Endocrine and Metabolic Research
CJC-1295 (with DAC) has been extensively studied in research models examining endocrine regulation and systemic metabolic signaling. Key areas of investigation include:
- Insulin-Like Growth Factor (IGF) Pathway Models: Evaluation of downstream signaling associated with prolonged growth hormone stimulation
- Protein Synthesis Signaling Research: Investigation of intracellular anabolic pathway activation
- Lipid and Glucose Metabolism Studies: Analysis of metabolic regulation under sustained endocrine signaling
- Energy Utilization and Substrate Switching: Research into systemic energy balance mechanisms
- Hormone Exposure Duration Models: Examination of physiological responses to extended hormonal stimulation
This body of research utilizes endocrine profiling systems, metabolic assays, and long-term hormone monitoring models to evaluate sustained signaling effects.
Pharmacokinetics and Extended Signal Duration Research
CJC-1295 (with DAC) is also examined in studies focused on long-acting peptide kinetics and signal persistence, including:
- Albumin Binding Dynamics: Evaluation of Drug Affinity Complex interactions with plasma proteins
- Signal Onset and Duration Studies: Investigation of extended receptor activation compared to short-acting analogs
- Plasma Stability Analysis: Research into degradation kinetics and systemic persistence in laboratory models
- Comparative Pharmacodynamic Profiles: Examination of sustained endocrine activation patterns
Laboratory protocols assess circulation time, receptor occupancy, and hormonal response curves using biochemical and analytical methodologies.
Cellular Signaling and Growth Pathway Research
Additional research applications explore CJC-1295 (with DAC)’s influence on intracellular growth-related signaling systems, including:
- MAPK and PI3K-AKT Pathway Studies: Investigation of downstream cascades associated with prolonged growth hormone signaling
- Gene Expression Profiling: Analysis of transcriptional responses under sustained endocrine stimulation
- Cellular Adaptation Mechanisms: Research into tissue responses to extended hormone exposure
- Homeostatic Feedback Systems: Examination of regulatory pathways maintaining endocrine balance
Research in this domain focuses on understanding how CJC-1295 (with DAC) modulates prolonged GHRH receptor signaling, endocrine dynamics, and downstream growth-related pathways under controlled experimental conditions.
Laboratory Handling and Storage Protocols
Lyophilized Powder Storage
- Store at –20°C to –80°C in the original, sealed vial
- Protect from light exposure and moisture
- A desiccated storage environment is recommended
- Stability data suggests extended stability when stored at −20 °C or below.
Reconstituted Solution Storage
- Short-term storage: Up to 7 days at 4°C
- Long-term storage: Store at –20°C in aliquots
- Use single-use aliquots to preserve peptide integrity
- Minimize freeze–thaw cycles; single-use aliquots are strongly recommended
Stability Characteristics
CJC-1295 (with DAC) is a modified synthetic peptide research compound designed for enhanced stability through Drug Affinity Complex (DAC) attachment. When handled under standard peptide laboratory protocols, including proper cold storage and careful reconstitution, it maintains structural integrity and solubility. Minimizing mechanical agitation and freeze–thaw exposure supports consistent performance in in vitro and analytical research applications.
Frequently Asked Questions
What is CJC-1295 (with DAC)?
CJC-1295 (with DAC) is a modified GHRH analog designed for extended activity in laboratory and preclinical models. The DAC modification allows prolonged receptor interaction in research settings.
What does the DAC modification do?
The Drug Affinity Complex (DAC) enables the peptide to bind to serum albumin in research models. This binding extends its circulation time and activity duration compared to the No DAC version.
What is CJC-1295 (with DAC) commonly researched for?
In experimental research environments, it is studied for:
-
GHRH receptor activation
-
Growth hormone release dynamics
-
IGF-1 pathway investigation
-
Endocrine and metabolic signaling research
All applications are exploratory and conducted in controlled laboratory or preclinical settings.
How does CJC-1295 (with DAC) differ from CJC-1295 (No DAC)?
The key difference is the presence of the DAC modification. The DAC version is engineered for extended activity duration, while the No DAC version has a shorter activity profile in comparative research models.
How is CJC-1295 (with DAC) supplied?
CJC-1295 (with DAC) is typically supplied as a lyophilized (freeze-dried) powder in sealed research vials to maintain stability during storage and transport.
How should unreconstituted CJC-1295 (with DAC) be stored?
Lyophilized peptide should be stored:
-
Long-term: −20 °C to −80 °C
-
Short-term: 2–8 °C
Keep vials sealed and protected from light and moisture.
How should reconstituted CJC-1295 (with DAC) be handled and stored?
Once reconstituted:
-
Store at 2–8 °C for short-term laboratory use
-
For longer-term storage, aliquot and freeze at −20 °C or below
-
Minimize freeze–thaw cycles using single-use aliquots
-
Gently swirl to mix; avoid vigorous agitation
Does CJC-1295 (with DAC) require a Certificate of Analysis (COA)?
Yes. A Certificate of Analysis (COA) should be available for each batch, confirming peptide identity, purity, and analytical testing results to ensure research quality and traceability.
Is CJC-1295 (with DAC) FDA-approved?
No. CJC-1295 (with DAC) is not FDA-approved as a drug, supplement, or therapeutic product. It is sold exclusively as a research compound and must not be marketed or used for diagnostic, therapeutic, or consumption purposes.
Research Background
For a referenced overview of what the published research examines — including why the human trials used only the DAC form, and what the literature does not establish — see What Is CJC-1295? Research Background, and DAC vs No DAC. It cites peer-reviewed sources and contains no dosing guidance.
This product is not for human consumption. It is sold strictly for research and educational purposes and is not intended to diagnose, treat, cure, or prevent any disease.
Any clinical data or research information referenced on this page is derived from peer-reviewed scientific literature and official publications. This information is provided for educational reference only and does not constitute medical advice or product claims.
By purchasing this product, you acknowledge that you are a qualified researcher and agree to use it in full compliance with all applicable laws and regulations.
